Visalytics
Visalytics
approved EB-2 (NIW)

Research Scientist

Biochemistry · India · 2025-04-22

Processing Time
165 days
Decision Date
2025-04-22
Location
California
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue his research in designing peptide-based therapeutics and long-acting prodrugs for the treatment of complex metabolic diseases such as type-2 diabetes and non-alcoholic steatohepatitis (NASH). His work focuses on developing oral and injectable formulations that improve patient adherence and reduce side effects. The endeavor aims to redefine drug delivery strategies and alleviate the economic and social burdens of chronic diseases in the U.S.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses critical metabolic diseases like type-2 diabetes and NASH, supporting U.S. pharmaceutical innovation and public health.

2 Well-positioned to Advance the Endeavor Met

The petitioner's record of 10 publications, 165 citations, and 50+ peer reviews demonstrates his capability to advance biochemical research.

3 Balance of Interests Met

The U.S. benefits from waiving the labor certification to retain a researcher whose work promises to lower healthcare costs and improve patient care.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 10 peer-reviewed journal articles (6 as first author), 2 conference abstracts, and 2 preprints. His research has garnered 165 citations and he has completed over 50 peer-review assignments, demonstrating his influence in the field. The case successfully satisfied all three Dhanasar prongs by linking his innovations to U.S. healthcare priorities and pharmaceutical leadership.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Conference Presentations
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Postdoctoral Researcher

Biotechnology · China

WeGreened EB-2 (NIW) approved
New York 169 days 2025-04-09
The petitioner proposes to continue research in the development of pharmacokinetics (PK) and pharmacodynamics (PD) studies, specifically focusing on the targeted delivery of anti-tumor and antimicrobial medications. This work involves synthesizing bioactive polymers, spatial metabolomics, and protein engineering to improve therapeutic efficacy. The endeavor aims to advance precision medications that reduce side effects for challenging diseases.
View Case

Research Scientist

Biotechnology · Iran

WeGreened EB-2 (NIW) approved
676 days 2025-10-22
The petitioner proposes to advance mechanistic understanding and treatment strategies for diabetes, cardiovascular disease, and oral cancer. The work focuses on uncovering biochemical drivers of metabolic disorders and identifying biomarkers to support earlier diagnosis and improved patient outcomes.
View Case

Research Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
Indiana 25 days 2023-10-20
The petitioner proposes to continue developing small-molecule ligands and chemical constituents for use in drug discovery and pharmaceutical development. This work focuses on the creation of anti-diabetic and anti-cancer compounds, as well as the design of FAP-targeted ligands with therapeutic applications. The research aims to advance pharmaceutical innovation and improve human health outcomes through more efficient drug synthesis methodologies.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Biotechnology cases More cases from India

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-04-22.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 165 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in India All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist